Form NPORT-P Voya Emerging Markets For: May 31
Tweet
Share
E-mailSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
- Pathfinder Ventures Inc. Provides Corporate Update
- Jayden Announces Shares-for-Debt Settlement
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
